Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paxerol
- Development stage
- Phase 2
- Lead developer
- Wellesley Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Paxerol** is an investigational fixed-dose oral combination of acetaminophen and ibuprofen developed for nocturia, including severe nocturia associated with overactive bladder. Each tablet contains acetaminophen 325 mg and ibuprofen 150 mg in a 50:50 immediate/sustained-release formulation intended for bedtime administration and prolonged overnight suppression of prostaglandin production. In a completed randomized Phase II trial, Paxerol was evaluated over 14 days at one, two, or three tablets nightly. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/26/NCT02646826/Prot_SAP_000.pdf))
- Brand names
- NocturolPaxerol
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Paxerol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paxerol.